MedPath

Prevalence of Pharyngolaryngeal Reflux in Patients Treated for Obstructive Sleep Apnea Syndrome

Not Applicable
Completed
Conditions
Obstructive Sleep Apnea
Reflux, Laryngopharyngeal
Registration Number
NCT05110352
Lead Sponsor
Elsan
Brief Summary

The aim of the study is to find, using validated and efficient tools, a laryngopharyngeal reflux in patients receiving polysomnography for suspected obstructive sleep apnea syndrome.

It is proposed to carry out simultaneously, at the Sleep Center of the Polyclinique of Poitiers (CSPP), a polysomnography, a 24-hour Restech pharyngeal pH-metry (day and night), a Peptest (in the evening and in the morning of the polysomnography), with the RSS-12 questionnaire and the RSA score.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
37
Inclusion Criteria
  • Adults (> 18 ans)
  • Polysomnography planned for OSA assessment
  • RPL known or not, suspected or not
  • Affiliation to a social security scheme or beneficiary of such a scheme
  • Patient having signed the free and informed consent
Exclusion Criteria
  • Minors
  • Smoking, alcoholism, chronic or serious disabling pathology
  • Medical history of upper aerodigestive tract cancer, radiotherapy
  • Recent infection of upper aerodigestive tract, chronic rhinosinusitis
  • Permanent nasal obstruction
  • Active allergy
  • Non-obstructive SAS (central)
  • Patient under anti-secretory treatment (IPP) during the 8 days preceding the Restech associated with the PSG
  • Refusal to participate in the study
  • Protected patients: Adults under guardianship, guardianship or other legal protection, deprived of liberty by judicial or administrative decision
  • Pregnant, breastfeeding or parturient
  • Hospitalized without consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Proportion of patients with Obstructive Sleep Apnea Syndrome diagnosed with pharyngolaryngeal reflux.3 months

the diagnosis of OSA is posed by the PSG as soon as the AHI is ≥ 15 / h

Secondary Outcome Measures
NameTimeMethod
Peptest3 months

Positive if \> 75 ng / mL

RSS-12 score3 months

Positive (\>11)

RSA score3 months

Positive if \> 14

Trial Locations

Locations (1)

Centre du Sommeil de la Polyclinique de Poitiers

🇫🇷

Potiers, France

Centre du Sommeil de la Polyclinique de Poitiers
🇫🇷Potiers, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.